Biotech: Page


  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Blackstone backs Alnylam with up to $2B investment

    The deal, which hands Blackstone royalty rights to an as-yet unapproved heart drug, is "one of the largest ever private financings of a biotech company," according to the firm.

    By • April 13, 2020
  • Eye drug side effects are real, Novartis confirms in new warning

    A recent review by the Swiss pharma found Beovu caused potentially serious side effects about once in every 1,000 injections.

    By • April 9, 2020
  • Explore the Trendline➔
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Myokardia at inflection point as heart drug readout nears

    Results are due soon from EXPLORER, Myokardia's first-ever Phase 3 study and a major test of the company's heart disease treatment mavacamten.

    By • April 9, 2020
  • Image attribution tooltip
    Roche
    Image attribution tooltip

    Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA

    The deal is one of the largest for a group of companies that aim to use small molecule drugs to block the function of RNA in the body's cells.

    By • April 8, 2020
  • Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    FDA delays decision on Roche spinal muscular atrophy drug

    Roche says the three-month delay is needed for the FDA to review new data for risdiplam, which could become the first oral option for the disabling and often fatal disorder.

    By • April 7, 2020
  • Image attribution tooltip
    Getty
    Image attribution tooltip

    Sage to lay off half of workforce in cost-cutting retrenchment

    The once high-flying biotech will significantly pare back spending, channeling resources toward recently redrawn plans for its lead antidepressant drug.

    By Ned Pagliarulo • April 7, 2020
  • Electron microscope image of SARS-CoV-2, isolated from a patient in the U.S.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
    Image attribution tooltip

    Inovio begins first human test of experimental coronavirus vaccine

    The biotech follows Moderna and China-based CanSino Biologics into the clinic with a vaccine, some three months after designing it. 

    By Ned Pagliarulo • April 7, 2020
  • Two test tubes pour different-colored liquids into a beaker in an illustration representative of biopharma mergers.
    Image attribution tooltip
    Elizabeth Regan/BioPharma Dive
    Image attribution tooltip

    Alnylam and Dicerna are pals now, which could spell trouble for Arrowhead

    All three biotechs are developing drugs for patients with a genetic condition called A1AT deficiency. A new collaboration between the first two puts pressure on Arrowhead.

    By • April 6, 2020
  • Image attribution tooltip
    GlaxoSmithKline
    Image attribution tooltip

    GSK bets $250M on Vir's antibody approach to treating coronavirus

    The companies aim to advance two antibodies developed by Vir directly into Phase 2 testing within the next three to five months, pending regulatory OK.

    By • April 6, 2020
  • A photo of a Gilead Sciences employee.
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead to lean on Second Genome's microbiome work in $38M research pact

    The four-year collaboration aims to unearth biomarkers that can help Gilead predict the benefit of drugs for diseases involving inflammation and fibrosis. 

    By • April 6, 2020
  • A logo of Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead working to quickly boost production of experimental coronavirus drug

    CEO Daniel O'Day said Gilead would provide at no charge its current supply of remdesivir, enough to treat some 140,000 patients with severe COVID-19. 

    By Ned Pagliarulo • April 6, 2020
  • Image attribution tooltip
    Rita Elena Serda
    Image attribution tooltip

    Fate inks $100M J&J pact for 'off-the-shelf' cancer cell therapies

    Several companies, including Fate, could soon provide meaningful data in support of allogeneic cell therapy, unless COVID-19 disrupts those plans.

    By • April 3, 2020
  • Sponsored by Parexel

    Commercial and regulatory strategy considerations for biotech

    Discover ideas and insights for getting innovations in the biotech pipeline to patients sooner. 

    By Alberto Grignolo, Corporate Vice President, Parexel; Sheela Hegde, Partner and Managing Director in Parexel’s Health Advances subsidiary; and Leslie DeVos, VP, Regulatory Consulting, Parexel • April 3, 2020
  • Image attribution tooltip
    Amgen
    Image attribution tooltip

    Amgen, partnering with Seattle's Adaptive, begins coronavirus drug search

    Like other drugmakers, the companies will screen antibodies from recovered COVID-19 patients to identify ones capable of neutralizing SARS-CoV-2. 

    By Ned Pagliarulo • April 2, 2020
  • Medical technicians work with patients at a COVID-19 Community-Based Testing Site at the PNC Bank Arts Center in Holmdel, N.J., March 23, 2020. The testing site, established in partnership with the Fe
    Image attribution tooltip
    Master Sgt. Hecht, Matt. (2020). [Photograph]. Retrieved from Flickr.
    Image attribution tooltip

    Under pressure, FDA touts speedy coronavirus drug development

    By redeploying staff and request "triaging," the agency says it has streamlined its process for approving use of experimental drugs for COVID-19.

    By • April 1, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Drugmakers await reckoning as doctors, patients make tough choices during pandemic

    Decisions to delay medical visits and treatment could have a ripple effect on the businesses of biotech and pharma companies.

    By , • April 1, 2020
  • Image attribution tooltip
    Elizabeth Regan/BioPharma Dive
    Image attribution tooltip

    A small NASH drugmaker finds positive data, but coronavirus makes for a 'tricky' path forward

    Results from a mid-stage study showed Akero Therapeutics' experimental drug could reduce liver fat in NASH patients, sending shares higher. 

    By • March 31, 2020
  • Image attribution tooltip
    Amarin
    Image attribution tooltip

    Amarin shares slump as surprising court defeat puts Vascepa at risk

    In what one analyst called a "serious blow," a federal court ruled patents held by Amarin on its heart drug Vascepa were obvious and therefore invalid. 

    By Ned Pagliarulo • March 31, 2020
  • Image attribution tooltip
    Courtesy of Bristol-Myers Squibb
    Image attribution tooltip

    With latest FDA submission, Bristol Myers keeps pace with Celgene milestones

    Bristol Myers' second cancer cell therapy is now on track to be approved before the deadline set in its $74 billion acquisition of Celgene last year. 

    By • March 31, 2020
  • A preparation of Gilead Sciences' CAR-T therapy Yescarta is readied in a manufacturing laboratory.
    Image attribution tooltip
    Courtesy of Gilead Sciences
    Image attribution tooltip

    For CAR-T, coronavirus brings uneven impact to studies, treatment

    Cancer cell therapy, approved only for the very sick, depends on a complex and precisely timed series of steps, all of which could be disrupted by COVID-19.

    By Ned Pagliarulo • March 27, 2020
  • Despite another delay, Intercept says its NASH drug remains on track

    The coronavirus outbreak, though, adds more uncertainty to what will be a closely watched regulatory review of Intercept's therapy.

    By • March 26, 2020
  • A sign reading Food and Drug Administration hangs over a building entrance.
    Image attribution tooltip

    Yujin Kim / MedTech Dive, original photo courtesy of U.S. Food and Drug Administration

    Image attribution tooltip

    Bluebird says gene therapy application delayed again, citing disagreement with FDA

    Discussions between Bluebird and the FDA are hung up on a release assay, data from which would be included in the company's application. 

    By Kristin Jensen • March 26, 2020
  • The entrance to Galapagos' corporate offices are lit up at dusk.
    Image attribution tooltip
    Courtesy of Galapagos
    Image attribution tooltip
    Q&A

    Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug

    The Belgian drugmaker announced this week that a series of Phase 2 and Phase 3 studies for filgotinib, an immune system regulator, had paused enrollment because of safety concerns related to COVID-19.

    By • March 25, 2020
  • Image attribution tooltip
    AstraZeneca
    Image attribution tooltip

    AstraZeneca turns again to UK's Silence in renewed RNAi push

    AstraZeneca and Silence Therapeutics, which first partnered in 2007, will team up to develop RNA interference drug candidates for diseases of the liver, heart, kidney and lung.

    By Ned Pagliarulo • Updated March 25, 2020
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Gilead, flooded with requests, suspends access to experimental coronavirus drug

    The biotech plans to transition to an expanded access program for remdesivir, which is being tested as a treatment for COVID-19 in five late-stage studies.

    By Ned Pagliarulo • March 23, 2020